Assertio-Garda deal analysis: what the Rolvedon-focused takeover means for specialty pharma investors
Find out why Assertio is being sold to Garda Therapeutics and what the Rolvedon-focused deal means for specialty pharma strategy.
Pharma & Biotech
Pharma & Biotech
What Cosette Pharmaceuticals’ first generic ciprofloxacin hydrocortisone launch reveals about FDA CGT incentives
Cosette Pharmaceuticals launches the first generic ciprofloxacin hydrocortisone otic suspension. Find out what this FDA CGT approval really changes.
Pharma & Biotech
What the Cosette–Mayne Pharma breakdown signals for future pharma M&A in Australia
Cosette Pharmaceuticals, Inc. has officially terminated its proposed AUD 7.40-per-share acquisition of Mayne Pharma Group Limited after the Australian government blocked the transaction. The decision was confirmed on December 9, 2025, and followed by Mayne Pharma’s own termination notice issued on December 11. The companies cited both the Treasurer of Australia’s ruling and the expiry